research Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer
A cancer patient's hair became permanently curly after treatment with nivolumab.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review
Nivolumab can cause hair loss as a rare side effect.
research Resolution of paraneoplastic alopecia areata following nivolumab in a patient with metastatic melanoma
Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.
research A case of bullous pemphigoid in a malignant melanoma patient following an increased Th2/Th1 ratio in peripheral blood cells after nivolumab treatment
Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.
research Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description
Nail changes from immunotherapy can be managed without stopping cancer treatment.
research Eosinophilic folliculitis of the scalp associated with PD‐1/PDL1 inhibitors
Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.
research Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
Skin side effects from melanoma immunotherapy are common and may indicate better survival.
research Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine
Immune cell-targeting biologics show potential for treating alopecia areata but need better-targeted therapies.
research Cemiplimab-Induced Alopecia Areata
A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
research ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
research 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research A bibliometric study of the top 100 most cited articles on melanoma: insights into research trends and characteristics
Melanoma research shifted focus to immunotherapy drugs after 2010, increasing their study and citations.
research Biological therapy in the treatment of melanoma
Biological therapy boosts the immune system to effectively fight melanoma.
research A Single-Arm, Open-Label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-Small Cell Lung Cancer
The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
research Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma
The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
research Decreased benzothiazole-type pheomelanin in regrown brown hair in alopecia areata
The girl's regrown brown hair had less of certain pigments than her original black hair.
research BH14 Multiple sclerosis and alopecia areata: drug-induced alopecia areata or coexisting autoimmune phenomena?
Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.
research The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.
research Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
research Cutaneous toxicities of new treatments for melanoma
New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
research Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia
Finasteride may cause side effects; more research needed.
research Perspectives in Head and Neck Medical Oncology
The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.
research Drug-induced vitiligo: a real-world pharmacovigilance analysis of the FAERS database
Certain drugs may cause vitiligo, so patients should be monitored.
research Alopecia areata and Homoeopathy
The document says homoeopathic treatments are good for hair regrowth in alopecia areata but doesn't give proof.
research Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
research Neoadjuvant Therapy with Disitamab Vedotin in Treating Muscle-Invasive Bladder Cancer: A Case Report
Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research Peptichemio: A New Oncolytic Drug in Combination with Vincristine and Prednisolone in the Treatment of Non-Hodgkin Lymphomas
The treatment was effective for advanced non-Hodgkin's lymphomas.